Korro Bio has caught the attention of analysts at Chardan, who have initiated coverage with a bullish outlook. The firm’s analysis suggests a staggering 90% potential upside for the company’s stock. This optimistic projection is based on Korro Bio’s innovative approach to genetic medicine. The company focuses on developing therapies that can edit RNA, offering new possibilities for treating genetic diseases. Chardan’s confidence in Korro Bio stems from the company’s promising pipeline and the potential impact of its RNA editing technology. These statistics highlight the significant growth potential that Korro Bio holds in the competitive field of genetic medicine.
Inder: ꀘꉻꋪ
@inderphull22
·
Feb 14 Im so hyped to be building in this space even though at times it can be so frustrating living in the CT echo chamber.We’ve got some of the best investors and globally recognised IP partners supporting
@KorProtocol
including publicly traded companies that are tokenising their
ROIresearch
@CraigGreenberg5
·
1h $AERGO investors indicate low-supply coins may surge. $GFI is also rising. $KRL, with under 50 million max supply and trading below $0.30, is a top sleeper.
AnotherBioInvestor
@AnotherBio
·
Apr 11 $KROS second this. Maybe I am reading too much into this, but I am interpreting this as a commitment to AT LEAST return excess capital, which should be at least ~400 million US$ or a tad under 10$ per share.
If you believe that, you´re paying ~2$ for ~4,50$ in cash remaining and
Bhavneesh Sharma MD, MBA (Finance)
@bs2537
·
20h Exciting times for $ABEO investors! EB-101 gene therapy shows huge promise for large, chronic wounds in EB—outshining $KRYS’s Vyjuvek with long-term healing (up to 5 yrs)! PDUFA set for Apr 29, 2025. Just bought it. Targeting $7, >50% upside. #Biotech #Investing
Einstein
@EinsteinBTC1
·
Mar 31 This quarter has been nothing short of shocking for alts, with many seemingly throwing in the towel.Meanwhile, $COR has held firm above support, with the team continuing to build behind the scenes and actively adding liquidity to strengthen the chart.Sooner or later,
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
